Zoetis company profile
Company profile
Zoetis has 14,500 employees and is headquartered in Parsippany, United States.
Based in Parsippany, New Jersey, Zoetis was founded in 1952 and works in animal health, covering the discovery, development, manufacture and sale of medicines, vaccines, diagnostic products, biodevices, genetic tests and precision animal health solutions. Its products are aimed mainly at companion animals such as dogs, cats and horses, and at livestock including cattle, swine, poultry, fish and sheep, and are marketed to veterinarians, livestock producers and pet owners. The range includes parasiticides, vaccines, dermatology products, anti-infectives, pain and sedation treatments, point-of-care diagnostics, rapid immunoassay tests and blood glucose monitors, as well as nutritional products. The company sells in the United States and in other markets worldwide, and it collaborates with Blacksmith Medicines to develop novel antibiotics for animal health.
In the fiscal year ended December 2025, Zoetis reported revenue of 9.5 billion US dollars, up 2.3% from the previous year, and net income of 2.7 billion US dollars. The company employed 14,500 people at the end of the period.
Company facts
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Headquarters
- 10 Sylvan Way, 07054, Parsippany
- Employees
- 14,500
- Chief executive
- Kristin Peck
- Founded
- 1952
- Fiscal year
- January - December
- Listing
- ZTS · NYSE
- Indices
- S&P 500
- Currency
- USD
- ISIN
- US98978V1035
- Website
- zoetis.com
Zoetis and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| ZoetisZTS | United States | $33.92B | 14,500 | 37.9% | 14.1 |
| United TherapeuticsUTHR | United States | $25.04B | 1,400 | 39.4% | 22.2 |
| ViatrisVTRS | United States | $23.58B | 30,000 | — | — |
| Teva Pharmaceutical IndustriesTEVA | United States | $49.67B | 31,173 | 19.8% | 99.0 |
| Neurocrine BiosciencesNBIX | United States | $16.73B | 2,500 | 26.6% | 24.5 |
| Hims & Hers HealthHIMS | United States | $4.13B | 2,442 | -6.4% | — |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
